Biomarker discovery in systemic sclerosis: state of the art

Systemic sclerosis (SSc) is an autoimmune disease characterized by immune dysfunction and by abnormalities of the microvasculature with vascular obliteration, eventually leading to fibrosis of the skin, gastrointestinal tract, lungs, heart, and kidney. The etiology and pathogenesis of SSc remain unc...

Full description

Saved in:
Bibliographic Details
Published in:Current biomarker findings 2015-01, Vol.5, p.47
Main Authors: Bonella, Francesco, Patuzzo, Giuseppe, Lunardi, Claudio
Format: Article
Language:English
Subjects:
Apoptosis
Arthritis
Biological markers
Biomarkers
Care and treatment
Collagen
Complications and side effects
Cytomegalovirus
Fibroblasts
Fibrosis
Gastrointestinal tract
Gene expression
Growth factors
Health aspects
Lung diseases
Lymphocytes
MicroRNAs
Mortality
Pathogenesis
Peptides
Proteins
Pulmonary fibrosis
Pulmonary hypertension
Rheumatology
Risk factors
RNA polymerase
Scleroderma
Scleroderma (Disease)
Systemic sclerosis
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Systemic sclerosis (SSc) is an autoimmune disease characterized by immune dysfunction and by abnormalities of the microvasculature with vascular obliteration, eventually leading to fibrosis of the skin, gastrointestinal tract, lungs, heart, and kidney. The etiology and pathogenesis of SSc remain unclear, despite recent significant progress in the field. Immune activation and microangiopathy are followed by widespread organ fibrosis, leading to organ failure and increased mortality. The production of inflammatory cytokines and growth factors after tissue injury, as well as the presence of circulating autoantibodies, provide a source of biomarkers with potential diagnostic and prognostic applications in the clinical routine. Two principal approaches exist to discover and characterize biomarkers. The proof-of-concept approach verifies the ability of known proteins, generally involved in the pathogenesis, to correlate with disease phenotype and outcome. A proteomic approach does not need prior knowledge of the proteins or of their function, but it requires high-performance and time-consuming techniques. In this review, we highlight the most recent findings in biomarkers used to characterize SSc organ involvement, to stratify the patients, and to assess the response to treatment.
ISSN:2230-2492
2230-2492
DOI:10.2147/CBF.S60446